Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 2/20 | 0.35 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18665455 | 0.84 | THRB (0.40) | MAPTTHRBALDH1A1TP53LMNA | |
| SCHEMBL14378120 | 0.82 | CYP1A2 (0.43) | MAPTTHRBALDH1A1MAPK1KDM4E | |
| SCHEMBL21180762 | 0.82 | MAPT (0.50) | MAPTHPGDALDH1A1TP53MAPK1 | |
| SCHEMBL22808237 | 0.82 | MAPT (0.50) | MAPTHPGDALDH1A1TP53MAPK1 | |
| SCHEMBL19151596 | 0.78 | CCNC (0.47) | MAPTTHRBALDH1A1TP53LMNA | |
| SCHEMBL22808234 | 0.77 | MAPT (0.45) | MAPTTHRBMAPK1KDM4EHSD17B10 | |
| SCHEMBL20086468 | 0.77 | MAPT (0.45) | MAPTTHRBALDH1A1TP53LMNA | |
| SCHEMBL20086406 | 0.76 | MAPT (0.44) | MAPTTHRBALDH1A1LMNAKDM4E | |
| SCHEMBL16691853 | 0.76 | THRB (0.52) | MAPTTHRBALDH1A1TP53LMNA | |
| SCHEMBL20086452 | 0.73 | MAPT (0.46) | MAPTHPGDALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350145-B1 | DNA BINDING AGENTS WITH A MINOR GROOVE BINDING TAIL | UNIV TEXAS (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10358439-B2 | DNA binding agents with a minor groove binding tail | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-07-23 | — | — | US | disclosed |
| WO-2017049091-A1 | DNA BINDING AGENTS WITH A MINOR GROOVE BINDING TAIL | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-03-23 | — | — | WO | disclosed |
| US-7301037-B2 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105135-A1 | Charged compounds comprising a nucleic acid binding moiety and uses therefor | POLRMT, PCNA, SARS1 | MAPT 4431/4885THRB 3881/4885HPGD 4065/4885 |
| US-10358439-B2 | DNA binding agents with a minor groove binding tail | TOP2B, TOP2A, TOP1 | MAPT 2623/4885THRB 1956/4885HPGD 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.